Abstract
DNA topoisomerase II-α (Topo II-α) is essential for numerous cell processes, including DNA replication, transcription, recombination, and chromosome separation and condensation. Altered Topo II-α expression may lead to carcinogenesis and cancer progression. The aim of the present study was to investigate the association between Topo II-α expression levels and clinicopathological data from laryngeal cancer patients. Immunohistochemistry was used to analyze Topo II-α expression in laryngeal squamous cell carcinoma and distant healthy tissues obtained from 70 patients. In addition, fluorescence in situ hybridization was used to detect Topo II-α amplification and chromosome 17 ploidy using a laryngeal cancer tissue microarray. The expression of Topo II-α protein was detected in 71.43% (50/70) of laryngeal carcinoma tissues, in contrast to 9% of healthy tissues (2/22). Furthermore, the expression of Topo II-α protein was found to be associated with tumor de-differentiation and advanced tumor T stage. However, the expression of Topo II-α protein was not identified to be associated with Topo II-α amplification in laryngeal carcinoma, although was found to positively correlate with chromosome 17 aneuploidy (P<0.05). A higher aneuploidy rate contributed to increased expression levels of Topo II-α protein. Aberrant Topo II-α expression and chromosome 17 aneuploidy contributed to the development and progression of laryngeal cancer, indicating that targeting Topo II-α may provide a treatment strategy for patients with laryngeal cancer.
Highlights
Laryngeal cancer is a common type of head and neck malignancy
Topo II‐α expression was positive in 71.43% (50/70) laryngeal cancer tissue specimens with a low expression rate of 52.11% (37/70) and high expression rate of 47.14% (33/70; Table I)
Low and high levels of Topo II‐α protein were observed in equal numbers of subglottic cancer tissue samples (50% [3/6]), no significant difference was identified between the expression of Topo II‐α protein and the different tumor localizations (P>0.05; Table II)
Summary
Laryngeal cancer is a common type of head and neck malignancy. In the United States, there were an estimated 12,260 novel cases of laryngeal cancer in 2013 [1]. Tobacco smoking and alcohol consumption are the most significant risk factors for laryngeal cancer, smoking cessation and decreased alcohol intake may reduce the incidence of this cancer [2]. The prognosis of patients with laryngeal cancer is closely associated with the tumor size, location, histological grade, patient age and the presence of lymph node or distant metastasis [3]. Novel approaches to identify biomarkers may facilitate clinicians with the early identification of laryngeal cancer and studies on the biological behavior of this cancer may provide valuable information for clinical treatment
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
